Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 3
2010 3
2011 5
2012 4
2013 8
2014 13
2015 21
2016 35
2017 33
2018 42
2019 37
2020 32
2021 43
2022 32
2023 42
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

322 results

Results by year

Filters applied: . Clear all
Page 1
Niclosamide as a Promising Therapeutic Player in Human Cancer and Other Diseases.
Wang Z, Ren J, Du J, Wang H, Liu J, Wang G. Wang Z, et al. Int J Mol Sci. 2022 Dec 17;23(24):16116. doi: 10.3390/ijms232416116. Int J Mol Sci. 2022. PMID: 36555754 Free PMC article. Review.
However, over the past few years, increasing evidence has shown that niclosamide could treat diseases beyond parasitic diseases, which include metabolic diseases, immune system diseases, bacterial and viral infections, asthma, arterial constriction, myopia, and cancer
However, over the past few years, increasing evidence has shown that niclosamide could treat diseases beyond parasitic diseases, whic …
New insights into niclosamide action: autophagy activation in colorectal cancer.
Newton PT. Newton PT. Biochem J. 2019 Mar 6;476(5):779-781. doi: 10.1042/BCJ20190020. Biochem J. 2019. PMID: 30842311 Review.
Amongst the most promising new therapies, niclosamide-an FDA-approved drug for treating tapeworm infections-is being assessed in a stage II clinical trial for the treatment of metastatic colorectal cancer. ...This finding provides a further understanding of the acti …
Amongst the most promising new therapies, niclosamide-an FDA-approved drug for treating tapeworm infections-is being assessed in a st …
Niclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities.
Barbosa EJ, Löbenberg R, de Araujo GLB, Bou-Chacra NA. Barbosa EJ, et al. Eur J Pharm Biopharm. 2019 Aug;141:58-69. doi: 10.1016/j.ejpb.2019.05.004. Epub 2019 May 9. Eur J Pharm Biopharm. 2019. PMID: 31078739 Review.
Drug repositioning may be defined as a process when new biological effects for known drugs are identified, leading to recommendations for new therapeutic applications. Niclosamide, present in the Model List of Essential Medicines, from the World Health Organization, has be …
Drug repositioning may be defined as a process when new biological effects for known drugs are identified, leading to recommendations for ne …
Niclosamide improves cancer immunotherapy by modulating RNA-binding protein HuR-mediated PD-L1 signaling.
Zhang Q, Yang Z, Hao X, Dandreo LJ, He L, Zhang Y, Wang F, Wu X, Xu L. Zhang Q, et al. Cell Biosci. 2023 Oct 17;13(1):192. doi: 10.1186/s13578-023-01137-w. Cell Biosci. 2023. PMID: 37848943 Free PMC article.
Niclosamide enhanced T cell-mediated killing of cancer cells and significantly improved the efficacy of anti-PD-1 immunotherapy in two syngeneic animal tumor models. ...Our study demonstrates a novel strategy for targeting HuR/PD-L1 and provides the first proof-of-p
Niclosamide enhanced T cell-mediated killing of cancer cells and significantly improved the efficacy of anti-PD-1 immunotherap
A dual-action niclosamide-based prodrug that targets cancer stem cells and inhibits TNBC metastasis.
Kim JH, Park S, Jung E, Shin J, Kim YJ, Kim JY, Sessler JL, Seo JH, Kim JS. Kim JH, et al. Proc Natl Acad Sci U S A. 2023 May 23;120(21):e2304081120. doi: 10.1073/pnas.2304081120. Epub 2023 May 15. Proc Natl Acad Sci U S A. 2023. PMID: 37186828 Free PMC article.
Here, we report a prodrug, Nic-A, created by combining a carbonic anhydrase IX (CAIX) inhibitor, acetazolamide, with a signal transducer and transcriptional activator 3 (STAT3) inhibitor, niclosamide. Nic-A was designed to target triple-negative breast cancer (TNBC) …
Here, we report a prodrug, Nic-A, created by combining a carbonic anhydrase IX (CAIX) inhibitor, acetazolamide, with a signal transducer and …
Niclosamide's potential direct targets in ovarian cancer.
Sekulovski N, MacLean JA, Bheemireddy SR, Yu Z, Okuda H, Pru C, Plunkett KN, Matzuk M, Hayashi K. Sekulovski N, et al. Biol Reprod. 2021 Aug 3;105(2):403-412. doi: 10.1093/biolre/ioab071. Biol Reprod. 2021. PMID: 33855343 Free PMC article.
Recent evidence indicates that niclosamide is an anti-cancer compound that is able to inhibit several signaling pathways. ...The present study identifies key signal transduction mechanisms altered by niclosamide in ovarian cancer. Using affinity purifi …
Recent evidence indicates that niclosamide is an anti-cancer compound that is able to inhibit several signaling pathways. ...T …
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.
Li Y, Li PK, Roberts MJ, Arend RC, Samant RS, Buchsbaum DJ. Li Y, et al. Cancer Lett. 2014 Jul 10;349(1):8-14. doi: 10.1016/j.canlet.2014.04.003. Epub 2014 Apr 13. Cancer Lett. 2014. PMID: 24732808 Free PMC article. Review.
A number of studies have established the anticancer activities of niclosamide in both in vitro and in vivo models. Moreover, the inhibitory effects of niclosamide on cancer stem cells provide further evidence for its consideration as a promising drug for c
A number of studies have established the anticancer activities of niclosamide in both in vitro and in vivo models. Moreover, the inhi …
Injectable pegylated niclosamide (polyethylene glycol-modified niclosamide) for cancer therapy.
Ma R, Ma ZG, Gao JL, Tai Y, Li LJ, Zhu HB, Li L, Dong DL, Sun ZJ. Ma R, et al. J Biomed Mater Res A. 2020 Jan;108(1):30-38. doi: 10.1002/jbm.a.36788. Epub 2019 Sep 5. J Biomed Mater Res A. 2020. PMID: 31433913
Niclosamide is an antihelminthic drug. Recent studies show that niclosamide exerts antitumor activity through inhibiting multiple signals including Wnt/beta-catenin, mTORC1, signal transducer and activator of transcription 3, NF-kappaB, notch signals; however, the i
Niclosamide is an antihelminthic drug. Recent studies show that niclosamide exerts antitumor activity through inhibiting multi
Niclosamide causes lysosome-dependent cell death in endometrial cancer cells and tumors.
Rai R, Dey DK, Benbrook DM, Chandra V. Rai R, et al. Biomed Pharmacother. 2023 May;161:114422. doi: 10.1016/j.biopha.2023.114422. Epub 2023 Feb 23. Biomed Pharmacother. 2023. PMID: 36841028 Free article.
In this study, we aimed to evaluate the efficacy of niclosamide (NIC) against endometrial cancer. NIC is an FDA-approved anti-helminthic drug, which has been recently extensively studied as a potent anti-cancerous agent in several cancers. The anti- …
In this study, we aimed to evaluate the efficacy of niclosamide (NIC) against endometrial cancer. NIC is an FDA-approved anti- …
Niclosamide in prostate cancer: An inhibitor of AR-V7, a mitochondrial uncoupler, or more?
Sakellakis M. Sakellakis M. Cancer Treat Res Commun. 2023;35:100685. doi: 10.1016/j.ctarc.2023.100685. Epub 2023 Jan 22. Cancer Treat Res Commun. 2023. PMID: 36706514 Free article.
A recent phase Ib study investigating the use of reformulated niclosamide in combination with abiraterone and prednisone in patients with castration-resistant prostate cancer (CRPC) demonstrated encouraging preliminary efficacy with low toxicity. ...However, some mi …
A recent phase Ib study investigating the use of reformulated niclosamide in combination with abiraterone and prednisone in patients …
322 results